Avandia
- Swiss Scientists Confirm Avandia's Link to Osteoporosis
- GlaxoSmithKline: Avandia Unlikely to Recover
- Warning Label Urged for Avandia
- Reports of Avandia-Related Heart Attacks Jumps
- Class Action Filed Against Avandia
- FDA Gave Glaxo Extra Year to Profit from Avandia
- Avandia- FDA Controversy Causes Questions of Comeback
- Diabetes Drug May Cause Heart Problems
- Is Avandia Safe? Depends Who You Ask.
- Avandia Heart Risks May Be "Inconclusive"
- Avandia May Get Bone Warning
- Congress Works to Balance Drug Safety and Fast Approval
- New Data Show Those Taking Avandia Had Lower Medical Costs
- Avandia Maker Sued Over Heart Attack
- Understanding How PPAR-Gamma Agonists Work
- Drug Similar to Avandia Actually Cuts Heart Risk
- Avandia Leads to Debate at Diabetes Meeting
- Warning to Avandia Patients in Canada
- GlaxoSmithKline Sued in Death of Man
- Link Between Avandia and Canadian Deaths Explored
- Perlegen Seeking Genes Responsible for Side Effects
- Avandia Hearing Says FDA is Negligent
- FDA May Lack Speed in Prescription Drug Reviews
- Diabetics Find Alternatives in Wake of Avandia Scare
- GlaxoSmithKline Sued by Shareholder
- Lawsuit Overshadows Glaxo's Launch of New Diet Pill
- Avandia Market Falls on Safety Concerns
- Rosiglitazone and Cardiotoxicity — Weighing the Evidence
- Avandia's Safety Defended by Glaxo
- Doctor Says Glaxo Pressured Him to Hush Criticism
- Information about the RECORD Study
- Questions Remain About Rosiglitazone Safety
- Rosiglitazone Evaluated for Cardiovascular Outcomes — An Interim Analysis
- New Data Suggests Avandia Does Not Show Health Risks
- Avandia Fiasco Questions U.S. Drug Approval System
